- Home
- IPG vs MRNA Comparison
IPG vs MRNA Comparison
Compare IPG & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPG
- MRNA
- Stock Information
- Founded
- IPG 1902
- MRNA 2010
- Country
- IPG United States
- MRNA United States
- Employees
- IPG N/A
- MRNA N/A
- Industry
- IPG Advertising
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IPG Consumer Discretionary
- MRNA Health Care
- Exchange
- IPG Nasdaq
- MRNA Nasdaq
- Market Cap
- IPG 9.9B
- MRNA 9.8B
- IPO Year
- IPG N/A
- MRNA 2018
- Fundamental
- Price
- IPG $26.52
- MRNA $28.54
- Analyst Decision
- IPG Buy
- MRNA Hold
- Analyst Count
- IPG 6
- MRNA 17
- Target Price
- IPG $31.02
- MRNA $42.40
- AVG Volume (30 Days)
- IPG 6.5M
- MRNA 12.5M
- Earning Date
- IPG 10-21-2025
- MRNA 11-06-2025
- Dividend Yield
- IPG 4.98%
- MRNA N/A
- EPS Growth
- IPG N/A
- MRNA N/A
- EPS
- IPG 1.18
- MRNA N/A
- Revenue
- IPG $8,846,600,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- IPG N/A
- MRNA N/A
- Revenue Next Year
- IPG $2.77
- MRNA $9.75
- P/E Ratio
- IPG $22.38
- MRNA N/A
- Revenue Growth
- IPG N/A
- MRNA N/A
- 52 Week Low
- IPG $22.51
- MRNA $23.15
- 52 Week High
- IPG $33.05
- MRNA $62.97
- Technical
- Relative Strength Index (RSI)
- IPG 51.31
- MRNA 64.44
- Support Level
- IPG $25.90
- MRNA $23.91
- Resistance Level
- IPG $28.42
- MRNA $27.10
- Average True Range (ATR)
- IPG 0.70
- MRNA 1.35
- MACD
- IPG 0.01
- MRNA 0.50
- Stochastic Oscillator
- IPG 37.95
- MRNA 93.00
About IPG Interpublic Group of Companies Inc. (The)
Interpublic Group is among the world's largest advertising holding companies based on annual revenue. It provides traditional advertising services along with digital and other services, such as public relations, through various acquisitions. IPG has made these services available in over 100 countries. The company generates about 65% of revenue in the US and 17% in the UK and Europe.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.